Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Molecular docking and dynamic simulation study to explore quercetin as a multi-potent candidate against gliomas

Syed Mohd Danish Rizvi¹, Talib Hussain², Khalid Mehmood^1,3, Afrasim Moin¹ , Abulrahman Sattam Alanazi⁴, Gehad M Subaiea²

¹Department of Pharmaceutics; ²Department of Pharmacology and Toxicology, College of Pharmacy, University of Hail, Hail, Saudi Arabia; ³Department of Pharmacy, Abbottabad University of Science and Technology, Havelian, Pakistan; ⁴Department of Clinical Pharmacy, College of Pharmacy, University of Hail, Hail, Saudi Arabia.

For correspondence:- Afrasim Moin Email: afrasimmoin@yahoo.co.in

Accepted: 21 March 2021 Published: 30 April 2021

Citation: Rizvi SM, Hussain T, Mehmood K, Moin A, Alanazi AS, Subaiea GM. Molecular docking and dynamic simulation study to explore quercetin as a multi-potent candidate against gliomas. Trop J Pharm Res 2021; 20(4):815-823 doi: 10.4314/tjpr.v20i4.23

© 2021 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To search for novel gliomas targets and their inhibitors using a molecular docking approach.

Methods: Quercetin multi-targeting potential was investigated against some of the emerging gliomas targets such as epidermal growth factor receptor (EGFR), ephrin type-A receptor 2 (EphA2), nicotinamide phosphoribosyltransferase (NMRPTase) and plasminogen activator inhibitor-1 (PAI-1). Crucial biochemical interaction of quercetin with these targets were analyzed using molecular docking study.

Results: Quercetin interacted strongly via hydrogen bonding with important active sites consisting of amino acid residues of EphA2 and PAI-1, and showed binding energy of -7.44 and -7.38 kcal/mol, respectively. Some crucial active site amino acids involved in the interaction of known EphA2 and PAI-1 inhibitors (Alw-II-41-27 and ACT001) were common in quercetin interactions as well, and both inhibitors as well as quercetin did not violate Lipinski rules. Importantly, the quercetin-EphA2 and quercetin-PAI-1 complexes were stable as minimal fluctuations within the permissible limit were observed during a 20 ns trajectory performed on desmond simulation platform.

Conclusion: Despite the fact that quercetin has been studied extensively against various cancer pathways, its transformation from a long-time bench candidate into bedside medications still needs further exploration. Nevertheless, the present predictive biochemical interaction analysis against emerging glioma targets might pave way for the design of novel therapeutic agents based on quercetin scaffolds.

Keywords: Ephrin type-A receptor 2, Gliomas, Molecular docking, Plasminogen activator inhibitor-1, Quercetin, Simulation analysis